Clinical trial

Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

NCT00315861

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-03-01

PhasePHASE1

Study timeline

Study start (unknown)2006-03-01Date precision: month

Registry last updated2009-01-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Ovarian Cancerunresolved

Endometrial Cancerunresolved

Cervical Cancerunresolved

Lung Cancerunresolved

Interventions

pemetrexedDRUG · verified · RxNorm: pemetrexed

topotecanDRUG · verified · RxNorm: topotecan

Sponsors & collaborators

SCRI Development Innovations, LLClead sponsor

GlaxoSmithKlinecollaborator

Eli Lilly and Companycollaborator

Mapped research locations

NashvilleTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00315861 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.